1. Platinum-based drugs: past, present and future

   • Shahana Dilruba
   • Ganna V. Kalayda

   Review Article 17 February 2016 Pages: 1103 - 1124

   

2. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib

   • Jeffrey C. Bryan
   • Srdan Verstovsek

   Review Article Open access 26 March 2016 Pages: 1125 - 1142

   

3. Phase II trial of biweekly docetaxel, cisplatin, and 5-fluorouracil chemotherapy for advanced esophageal squamous cell carcinoma

   • Yoshihiro Tanaka
   • Kazuhiro Yoshida
   • Tatsuhiko Miyazaki

   Original Article Open access 20 February 2016 Pages: 1143 - 1152

4. Erratum to: Phase II trial of biweekly docetaxel, cisplatin, and 5-fluorouracil chemotherapy for advanced esophageal squamous cell carcinoma

   • Yoshihiro Tanaka
   • Kazuhiro Yoshida
   • Tatsuhiko Miyazaki

   Erratum 25 April 2016 Pages: 1153 - 1155

5. A phase I study of binimetinib (MEK162) in Japanese patients with advanced solid tumors

   • K. Watanabe
   • S. Otsu
   • Y. Ando

   Original Article 12 April 2016 Pages: 1157 - 1164

   

6. The combination of HLA-B*15:01 and DRB1*15:01 is associated with gemcitabine plus erlotinib-induced interstitial lung disease in patients with advanced pancreatic cancer

   • Meiko Nishimura
   • Masanori Toyoda
   • Hironobu Minami

   Original Article Open access 21 April 2016 Pages: 1165 - 1170

   

7. Tanshinone I induces apoptosis and pro-survival autophagy in gastric cancers

   • Xiaoping Jing
   • Yichun Xu
   • Li He

   Original Article 21 April 2016 Pages: 1171 - 1181

   

8. A meta-analysis identifies ERCC1 gene polymorphism as a predictor of better patient response to treatment with radiochemotherapy

   • Fengying Li
   • Xinyou Xie
   • Jun Zhang

   Original Article 21 April 2016 Pages: 1183 - 1191

   

9. Phase I study of safety and tolerability of sunitinib in combination with sirolimus in patients with refractory solid malignancies and determination of VEGF (VEGF-A) and soluble VEGF-R2 (sVEGFR2) in plasma

   • Jia Li
   • Harriet Kluger
   • Muhammad Wasif Saif

   Original Article 21 April 2016 Pages: 1193 - 1200

   

10. A phase 0 clinical trial of novel candidate extended-release formulations of capecitabine

    • Bart A.W. Jacobs
    • Jelte Meulenaar
    • Serena Marchetti

    Original Article 21 April 2016 Pages: 1201 - 1207

    

11. Hypomagnesemia is a reliable predictor for efficacy of anti-EGFR monoclonal antibody used in combination with first-line chemotherapy for metastatic colorectal cancer

    • Hironori Fujii
    • Hirotoshi Iihara
    • Yoshinori Itoh

    Original Article 22 April 2016 Pages: 1209 - 1215

    

12. YSL-12, a novel microtubule-destabilizing agent, exerts potent anti-tumor activity against colon cancer in vitro and in vivo

    • De Cai
    • Zhiqing Qiu
    • Zhixiu Lin

    Original Article 23 April 2016 Pages: 1217 - 1229

    

13. Evaluation of artemisinins for the treatment of acute myeloid leukemia

    • Christina D. Drenberg
    • Jassada Buaboonnam
    • Sharyn D. Baker

    Original Article 28 April 2016 Pages: 1231 - 1243

    

14. Safety and efficacy of S-1 in combination with carboplatin in non-small cell lung cancer patients with interstitial lung disease: a pilot study

    • Akimasa Sekine
    • Hiroaki Satoh
    • Terufumi Kato

    Original Article 29 April 2016 Pages: 1245 - 1252

    

15. A phase I study evaluating cixutumumab, a type 1 insulin-like growth factor receptor inhibitor, given every 2 or 3 weeks in Japanese patients with advanced solid tumors

    • Toshihiko Doi
    • Kohei Shitara
    • Atsushi Ohtsu

    Original Article 30 April 2016 Pages: 1253 - 1262

    

16. Mechanism-based modeling of the clinical effects of bevacizumab and everolimus on vestibular schwannomas of patients with neurofibromatosis type 2

    • Aziz Ouerdani
    • Stéphane Goutagny
    • Benjamin Ribba

    Original Article 04 May 2016 Pages: 1263 - 1273

    

17. Phase 1 study of cardiac safety of TAS-102 in patients with advanced solid tumors

    • Johanna C. Bendell
    • Manish R. Patel
    • Hendrik-Tobias Arkenau

    Original Article Open access 05 May 2016 Pages: 1275 - 1283

    

18. Predictive value of GSTP1 Ile105Val polymorphism in clinical outcomes of chemotherapy in gastric and colorectal cancers: a systematic review and meta-analysis

    • Xiaobing Shen
    • Jia Wang
    • Yuchao Xu

    Original Article 06 May 2016 Pages: 1285 - 1302

    

19. A comprehensive pharmacokinetic/pharmacodynamics analysis of the novel IGF1R/INSR inhibitor BI 893923 applying in vitro, in vivo and in silico modeling techniques

    • Melanie I. Titze
    • Otmar Schaaf
    • Thorsten Lehr

    Original Article 09 May 2016 Pages: 1303 - 1314

    

20. Phase II trial of concurrent bio-chemoradiotherapy using docetaxel, cisplatin, and cetuximab for locally advanced head and neck squamous cell carcinoma

    • Goshi Nishimura
    • Takahide Taguchi
    • Nobuhiko Oridate

    Clinical Trial Report 06 May 2016 Pages: 1315 - 1319

    

21. Erratum to: Investigation of ototoxicity of artesunate as add-on therapy in patients with metastatic or locally advanced breast cancer: new audiological results from a prospective, open, uncontrolled, monocentric phase I study

    • Miriam König
    • Cornelia von Hagens
    • Serkan Sertel

    Erratum 19 April 2016 Pages: 1321 - 1321